Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.
Copyright policy )Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.
Aclidinium bromide is a novel, inhaled, long-acting antimuscarinic agent being developed by Almirall Prodesfarma SA and Forest Laboratories Inc as a once-daily treatment for COPD. In preclinical studies, aclidinium bromide demonstrated a comparable profile to tiotropium bromide, with a slightly quicker onset of action but shorter duration of action. Clinical trials have demonstrated an unquestionably interesting pharmacological profile characterized by a faster rate of onset of the smooth muscle relaxing activity than tiotropium bromide and a rapid plasma hydrolysis in human plasma to inactive metabolites that may account for its favorable cardiovascular safety profile. However, the disappointing efficacy results of the recent phase III trials have cast doubt on the real advantage of introducing this drug on the market. Discussions with the FDA concluded that more trials are needed to assess selected dosing regimens, including higher and/or more frequent doses. At the time of publication, further phase III trials with aclidinium bromide were ongoing, and the developing companies were also extending development to combinations of aclidinium bromide with formoterol or an undisclosed inhaled corticosteroid.
corticosteroid, lip disease, drug safety, dysphagia, muscarinic M3 receptor antagonist, diarrhea, Drug Evaluation, Preclinical, formoterol, 610, Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO, Muscarinic Antagonists, beta adrenergic receptor stimulating agent, aclidinium bromide, Pulmonary Disease, Chronic Obstructive, drug activity, cholinergic receptor blocking agent, tiotropium bromide, Animals, Humans, human, rhinopharyngiti, xerostomia, coughing, long acting drug, Receptor, Muscarinic M3, Clinical Trials as Topic, nonhuman, article, clinical trial, Drugs, Investigational, aclidinium bromide; beta adrenergic receptor stimulating agent; cholinergic receptor blocking agent; corticosteroid; formoterol; las 35783; long acting drug; moxifloxacin; muscarinic M3 receptor antagonist; placebo; tiotropium bromide; unclassified drug; article; chronic obstructive lung disease; clinical trial; coughing; diarrhea; drug activity; drug dose comparison; drug efficacy; drug hydrolysis; drug safety; dry lip; dysphagia; headache; human; lip disease; nausea; nonhuman; rhinopharyngitis; smooth muscle relaxation; xerostomia, nausea, drug hydrolysi, unclassified drug, Bronchodilator Agents, drug efficacy, drug dose comparison, Delayed-Action Preparations, las 35783, dry lip, placebo, moxifloxacin, headache, smooth muscle relaxation, chronic obstructive lung disease, Tropanes
corticosteroid, lip disease, drug safety, dysphagia, muscarinic M3 receptor antagonist, diarrhea, Drug Evaluation, Preclinical, formoterol, 610, Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO, Muscarinic Antagonists, beta adrenergic receptor stimulating agent, aclidinium bromide, Pulmonary Disease, Chronic Obstructive, drug activity, cholinergic receptor blocking agent, tiotropium bromide, Animals, Humans, human, rhinopharyngiti, xerostomia, coughing, long acting drug, Receptor, Muscarinic M3, Clinical Trials as Topic, nonhuman, article, clinical trial, Drugs, Investigational, aclidinium bromide; beta adrenergic receptor stimulating agent; cholinergic receptor blocking agent; corticosteroid; formoterol; las 35783; long acting drug; moxifloxacin; muscarinic M3 receptor antagonist; placebo; tiotropium bromide; unclassified drug; article; chronic obstructive lung disease; clinical trial; coughing; diarrhea; drug activity; drug dose comparison; drug efficacy; drug hydrolysis; drug safety; dry lip; dysphagia; headache; human; lip disease; nausea; nonhuman; rhinopharyngitis; smooth muscle relaxation; xerostomia, nausea, drug hydrolysi, unclassified drug, Bronchodilator Agents, drug efficacy, drug dose comparison, Delayed-Action Preparations, las 35783, dry lip, placebo, moxifloxacin, headache, smooth muscle relaxation, chronic obstructive lung disease, Tropanes
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).23 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!